Key Events This Week
31 Aug: Stock opens at Rs.0.50, flat on the day
01 Sep: Hits all-time low at Rs.0.49 amid prolonged downtrend
02 Sep: Falls further to 52-week low of Rs.0.48
03 Sep: Maintains all-time low at Rs.0.48 despite slight intraday gains
04 Sep: Closes week at Rs.0.49 after hitting all-time low again
31 August 2026: Flat Start Amid Market Weakness
Shree Ganesh Biotech India Ltd opened the week at Rs.0.50, unchanged from the previous close, despite the Sensex falling 0.48% to 36,615.95. The stock’s volume was moderate at 567,579 shares, signalling a cautious start amid broader market weakness. The lack of price movement contrasted with the Sensex’s decline, indicating early signs of relative stability before the subsequent downtrend.
1 September 2026: All-Time Low at Rs.0.49 Highlights Prolonged Downtrend
The stock slipped to a new all-time low of Rs.0.49 on 1 September, marking a significant milestone in its ongoing decline. This represented a 37.5% drop from its 52-week high of Rs.0.80. Despite the broader market’s 0.30% decline in the Sensex, the stock marginally outperformed its sector by 0.31% on the day but remained below all key moving averages, signalling persistent selling pressure. Financial metrics revealed deteriorating fundamentals, with the company reporting negative EBITDA of Rs. -1.76 crore and a quarterly PBDIT of Rs. -0.89 crore, underscoring operational challenges.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
2 September 2026: Stock Falls to 52-Week Low of Rs.0.48 Amid Sector Weakness
On 2 September, the stock declined further to Rs.0.48, a fresh 52-week and all-time low, down 2.00% on the day. This underperformance was sharper than the Pharmaceuticals & Biotechnology sector’s 2.17% decline and the Sensex’s 0.44% fall. The stock remained below all key moving averages, reinforcing a sustained bearish trend. Financially, the company’s earnings contracted by 86% over the past year, with EPS at a negative Rs.0.01 for the quarter. The company’s debt servicing capacity remained weak, with an EBIT to interest coverage ratio of just 0.35x, highlighting limited ability to meet interest obligations.
3 September 2026: Continued Downtrend Despite Slight Intraday Gains
Despite a modest intraday gain of 2.08% on 3 September, the stock closed at Rs.0.48, maintaining its all-time low. This price level represents a 40.0% decline from the 52-week high of Rs.0.80. The stock’s technical indicators remained bearish, with weekly MACD and KST confirming downward momentum. Delivery volumes increased significantly, with a 149.08% rise compared to the 5-day average, suggesting heightened trading activity amid the downtrend. The company’s Mojo Score of 12.0 and a Strong Sell rating by MarketsMOJO reflect deteriorated fundamentals and elevated risk.
Is Shree Ganesh Biotech India Ltd your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
4 September 2026: Week Closes at Rs.0.49 After Testing All-Time Low
The stock closed the week at Rs.0.49 on 4 September, after touching an all-time low of Rs.0.48 during the session. Despite a modest intraday gain of 2.08%, the stock remains significantly below its 52-week high, reflecting sustained bearish sentiment. The company’s financial position remains challenged, with negative EBITDA and the lowest quarterly PBDIT and PBT levels recorded. The stock’s valuation multiples, including a price-to-book ratio of 0.30x and negative EV/EBITDA and EV/EBIT ratios, underscore its loss-making status. Institutional shareholding remains low at 1.42%, with the majority held by non-institutional investors. The absence of promoter share pledging is a positive governance aspect amid ongoing financial difficulties.
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-08-31 | Rs.0.50 | +0.00% | 36,615.95 | -0.48% |
| 2026-09-01 | Rs.0.50 | +0.00% | 36,506.61 | -0.30% |
| 2026-09-02 | Rs.0.48 | -4.00% | 36,344.55 | -0.44% |
| 2026-09-03 | Rs.0.48 | +0.00% | 36,315.81 | -0.08% |
| 2026-09-04 | Rs.0.49 | +2.08% | 36,385.87 | +0.19% |
Key Takeaways
Shree Ganesh Biotech India Ltd’s stock performance this week highlights several critical factors:
- The stock hit multiple all-time and 52-week lows, closing the week down 2.00%, underperforming the Sensex’s 1.11% decline.
- Financial metrics remain weak, with negative EBITDA of Rs. -1.76 crore and quarterly PBDIT and PBT at their lowest levels of Rs. -0.89 crore.
- Technical indicators are firmly bearish, with the stock trading below all key moving averages and negative MACD and KST signals.
- Institutional shareholding is minimal at 1.42%, with majority ownership by non-institutional investors, potentially impacting liquidity.
- Despite being a net cash company with no promoter share pledging, the company’s profitability and growth metrics remain below average, contributing to a Strong Sell rating by MarketsMOJO.
Conclusion
The week under review has reinforced the challenging environment facing Shree Ganesh Biotech India Ltd. The stock’s persistent decline to all-time lows amid weak financial results and bearish technical signals underscores the severity of its current position. While the company maintains a net cash status and good capital structure, its ongoing losses, poor profitability ratios, and subdued market sentiment continue to weigh heavily on its valuation and trading levels. The stock’s underperformance relative to the Sensex and sector peers, combined with a Strong Sell rating, reflects the elevated risks and limited near-term prospects for recovery.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
